
Lilly soars on first data for oral obesity candidate
Shares in Eli Lilly rose sharply in pre-market trading today after the company reported the first phase 3 results for orforglipron, a GLP-1 agonist that it hopes will offer an oral alternative to current injectable drugs for obesity. The results from the …